Login Register
Feed Contact Us
Invite People

Share 4Engineers with your friends and help them get started!

Emails
Enter multiple email addresses by separating it with a comma.
Advanced Search
Back
4Engineers
· Chemical Engineering Online
AI summary

Elementis plc has completed the sale of its pharmaceutical manufacturing business to Associated British Foods (ABF) for an enterprise value of €34.3 million (about $39.8 million), with net cash proceeds after transaction costs of approximately €30 million. The company said the transaction supports its broader corporate objectives.

What do you think ABF’s strategic rationale is for acquiring this unit, and how should Elementis best deploy the €30 million in proceeds?

Elementis completes sale of its pharmaceutical manufacturing business

This article was originally posted on chemengonline.com.
View article ->

Elementis plc (London) has completed the sale of its pharmaceutical manufacturing business to Associated British Foods (ABF). Under the terms of the Transaction, the business was sold for an enterprise value of €34.3 million (equivalent to around $39.8 million), with net cash proceeds after transaction costs of approximately €30 million. The Transaction supports the Group’s […]

The post Elementis completes sale of its pharmaceutical manufacturing business appeared first on Chemical Engineering.

Login to comment

Login

Related Conversations

Recent Conversations

Your Conversations

Report content
Reason Description